Reach Us +44-1477412632
Design Of A Randomized Controlled Clinical Trial Assessing Dietary Sodium Restriction And Hemodialysis Related Symptom Profiles | 61472
ISSN: 2161-0959

Journal of Nephrology & Therapeutics
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Design of a randomized controlled clinical trial assessing dietary sodium restriction and hemodialysis related symptom profiles

10th European Nephrology Conference

Maya N Clark Cutaia

University of Pennsylvania School of Nursing, USA

Posters & Accepted Abstracts: J Nephrol Ther

DOI: 10.4172/2161-0959.C1.034

Aim: In hemodialysis, patients need to have intercurrent sodium and water intake removed by ultrafiltration, increases disease burden through the symptoms and signs that occur during hemodialysis (HD). This added burden may be mitigated by reduction of dietary sodium. The National Kidney Foundation (NKF) recommends 2400 mg of dietary sodium daily for patients on HD, and the American Heart Association (AHA) suggests 1500 mg, evidence is lacking, however, to support these recommendations in HD. Moreover, little is known about the relationship of specific levels of dietary sodium intake and the severity of symptoms and signs during ultrafiltration. Our goal will be to determine the effects of carefully-monitored levels of sodium-intake as set forth by the NKF and AHA on symptoms and signs in patients undergoing (HD). Methods: We designed a 3-group (2400 mg, 1500 mg, unrestricted), double blinded randomized controlled trial with a sample of 42 HD participants to determine: Whether symptom profiles and interdialytic weight gain vary among 3 sodium intake groups; the effect of HD-specific on the symptom profiles vary among the 3 groups; and whether total body water extracellular volume and intracellular volume measured with bioimpedance varies across the 3 groups. We will also examine the feasibility of recruitment, enrollment and retention of participants for the 5-day inpatient stay. Conclusion: Curbing sodium intake may lead to improvement in intradialytic symptom amelioration and potential for better longterm outcomes. Generating empirical support will be critical to ascertain and espouse the appropriate level of sodium intake for patients receiving HD.

Maya N Clark Cutaia received her PhD from the University of Pittsburgh, School of Nursing, and completed her Post-doctoral work at the University of Pennsylvania, School of Nursing. She is faculty in the Adult Gerontological Acute Care Nurse Practitioner Program, while conducting research that will lead to development and testing of bio-behavioral interventions for symptom management based on explicating biological mechanisms. Her current focus is symptom management in ESRD, with an interest in the impact of recommended dietary sodium intake restrictions on symptoms experienced by hemodialysis patients.

Email: [email protected]